• Dupilumab Gets First FDA-Approved Indication for Prurigo Nodularis

    2 monthes ago - By MedPageToday

    The FDA has approved dupilumab as the first treatment with an indication for prurigo nodularis, Sanofi announced.
    A chronic inflammatory skin condition affecting about 75,000 Americans, prurigo nodularis causes persistent...
    Read more ...

     

  • FDA Approves Dupilumab for Treatment of Prurigo Nodularis

    FDA Approves Dupilumab for Treatment of Prurigo Nodularis

    2 monthes ago - By Medscape

    In phase 3 trials, patients showed clinically meaningful reductions in itchiness and skin lesions with dupilumab compared with placebo.
    Medscape Medical News
    Read more ...

     

  • Dupixent approved for prurigo nodularis treatment

    Dupixent approved for prurigo nodularis treatment

    2 monthes ago - By Healio

    The FDA has approved Dupixent for the treatment of prurigo nodularis in adults, Regeneron and Sanofi announced in a press release.
    Dupixent , given as a subcutaneous injection, is the first drug approved by the FDA for this indication.
    Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life disruptions, affects approximately 75,000 adults in the United States.
    “Until today, there were limited treatment options to manage the relentless itch and associated sensations of burning and stinging skin that can negatively impact the lives
    Read more ...